Hematology prior authorization at CareFirst BCBS
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
CareFirst BCBS hematology PA at a glance
CareFirst BCBS reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where CareFirst BCBS's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
- Step therapy on specialty drugs via CVS Caremark
Appeal angles when CareFirst BCBS denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at CareFirst BCBS
Deep dives on each drug's PA criteria at CareFirst BCBS:
Frequently asked questions
What documentation does CareFirst BCBS need for hematology prior authorizations?
CareFirst BCBS's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at CareFirst BCBS?
CareFirst BCBS standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which hematology drugs does CareFirst BCBS most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in CareFirst BCBS's medical policy library.
How do I prep a peer-to-peer with CareFirst BCBS in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to CareFirst BCBS's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com